Acutaas Chemicals Q1FY27 Consolidated Profit ₹749.93 Crore, Revenue ₹329.67 Crore
Acutaas Chemicals reported consolidated revenue of ₹329.67 crore and profit after tax of ₹74.99 crore for Q1FY27. Standalone profit after tax was ₹75.90 crore. The company's shareholding in a subsidiary diluted to 90% in May 2026. A tax inspection concluded with no expected material impact.
The results show improved profitability, which is a key indicator for investors. The dilution of subsidiary holding and the tax inspection are also notable, though management expects no material impact from the latter.
The company reported a significant increase in consolidated profit after tax for the quarter ended June 30, 2026, compared to the same period last year, indicating positive financial performance.
Acutaas Chemicals Limited (formerly known as Ami Organics Limited) announced its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The Board of Directors, at their meeting held on July 24, 2026, approved these results, which were recommended by the Audit Committee.
The consolidated revenue from operations for the quarter stood at ₹32,967.48 lakhs (₹329.67 crore), with total income at ₹33,147.61 lakhs (₹331.48 crore). Consolidated profit after tax for the period was ₹7,499.27 lakhs (₹74.99 crore), a significant increase from ₹4,401.05 lakhs (₹44.01 crore) in the same quarter last year. The total comprehensive income attributable to owners of the company was ₹7,283.27 lakhs (₹72.83 crore).
On a standalone basis, revenue from operations was ₹32,240.92 lakhs (₹322.41 crore), and profit after tax was ₹7,589.57 lakhs (₹75.90 crore). The company also noted that during the quarter, its shareholding in its subsidiary, Acutaas Chemicals Electrolytes Private Limited, diluted from 100% to 90% due to a preferential issue, but this did not affect the company's control. Additionally, a CGST & CE inspection at the Surat facility concluded on June 23, 2026, with management not expecting any material impact.
What to do with a filing like this
Acutaas Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Acutaas Chemicals Limited. Read the original for the full detail.